9.19
price down icon0.76%   -0.07
after-market After Hours: 9.19
loading
Viatris Inc stock is traded at $9.19, with a volume of 7.07M. It is down -0.76% in the last 24 hours and up +2.00% over the past month. Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
See More
Previous Close:
$9.26
Open:
$9.24
24h Volume:
7.07M
Relative Volume:
0.55
Market Cap:
$10.79B
Revenue:
$14.33B
Net Income/Loss:
$-3.79B
P/E Ratio:
-2.8991
EPS:
-3.17
Net Cash Flow:
$1.84B
1W Performance:
-0.54%
1M Performance:
+2.00%
6M Performance:
-18.89%
1Y Performance:
-22.77%
1-Day Range:
Value
$9.125
$9.24
1-Week Range:
Value
$9.125
$9.42
52-Week Range:
Value
$6.85
$13.55

Viatris Inc Stock (VTRS) Company Profile

Name
Name
Viatris Inc
Name
Phone
(724) 514-1465
Name
Address
1000 MYLAN BOULEVARD, CANONSBURG
Name
Employee
32,000
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
VTRS's Discussions on Twitter

Compare VTRS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
VTRS
Viatris Inc
9.19 10.87B 14.33B -3.79B 1.84B -3.17
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
151.01 67.12B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.32 45.19B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.81 43.57B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.54 18.93B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
297.56 13.45B 2.99B 1.21B 1.13B 25.06

Viatris Inc Stock (VTRS) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-06-25 Initiated Goldman Neutral
Jul-19-24 Resumed Jefferies Buy
Oct-23-23 Downgrade BofA Securities Neutral → Underperform
Jun-23-23 Downgrade Barclays Equal Weight → Underweight
Apr-24-23 Downgrade Barclays Overweight → Equal Weight
Feb-17-23 Downgrade BMO Capital Markets Outperform → Market Perform
Jan-27-23 Upgrade Jefferies Hold → Buy
Nov-10-22 Upgrade UBS Sell → Neutral
Nov-08-22 Upgrade Piper Sandler Underweight → Neutral
Oct-21-22 Resumed Jefferies Hold
Jun-14-22 Initiated UBS Sell
May-10-22 Downgrade Piper Sandler Neutral → Underweight
Mar-01-22 Downgrade BofA Securities Buy → Neutral
Mar-01-22 Downgrade Raymond James Outperform → Mkt Perform
Jun-15-21 Initiated Citigroup Neutral
Apr-07-21 Resumed RBC Capital Mkts Outperform
Mar-08-21 Downgrade Goldman Buy → Neutral
Mar-02-21 Downgrade JP Morgan Overweight → Neutral
Feb-26-21 Downgrade Wolfe Research Outperform → Peer Perform
Jan-05-21 Initiated Argus Hold
Dec-14-20 Initiated Bernstein Mkt Perform
View All

Viatris Inc Stock (VTRS) Latest News

pulisher
04:11 AM

Anchoring Your Portfolio: Is VTRS Stock a Safe Harbor? - investchronicle.com

04:11 AM
pulisher
07:59 AM

What data driven models say about Viatris Inc.’s futureHigh Return Trade Roadmap with Setup Filters - Newser

07:59 AM
pulisher
03:57 AM

Influenza Vaccine Market is projected to grow to US$ 13.75 - openPR.com

03:57 AM
pulisher
03:55 AM

Lidocaine Vial Market Set to Witness Significant Growth by 2033 | - openPR.com

03:55 AM
pulisher
02:25 AM

Neurovascular Guidewires Market Outlook 2025 to 2035: Growth - openPR.com

02:25 AM
pulisher
Jul 28, 2025

US Court Agrees To Throw Out Viatris Wegovy Infringement Case - insights.citeline.com

Jul 28, 2025
pulisher
Jul 28, 2025

How to interpret RSI for Viatris Inc. stockMomentum Stocks with Breakout Potential - Newser

Jul 28, 2025
pulisher
Jul 28, 2025

Why Viatris Inc. stock attracts strong analyst attention Daily Trade Monitor with Pattern Alerts - Newser

Jul 28, 2025
pulisher
Jul 28, 2025

Why is Viatris Inc. stock attracting strong analyst attentionInvest in high-yield stocks with confidence - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How strong is Viatris Inc. company’s balance sheetAchieve rapid financial growth with expert help - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

Should I hold or sell Viatris Inc. stock in 2025Maximize portfolio value with expert tips - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

How does Viatris Inc. compare to its industry peersFree Bull & Bear Market Updates - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

How volatile is Viatris Inc. stock compared to the marketUnprecedented profit potential - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Competitive Positioning of Viatris Inc.: Is It Leading or LaggingFree Consultation - Newser

Jul 27, 2025
pulisher
Jul 26, 2025

Why Viatris Inc. stock attracts strong analyst attentionSmart High Yield Swing Trades - metal.it

Jul 26, 2025
pulisher
Jul 25, 2025

What analysts say about Viatris Inc. stockTremendous wealth creation - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What drives Viatris Inc. stock priceMarket-crushing profits - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

What institutions are buying Viatris Inc. stock nowUnprecedented growth rates - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

Bausch Health adds two pharmaceutical industry veterans to board By Investing.com - Investing.com Nigeria

Jul 24, 2025
pulisher
Jul 24, 2025

Bausch Health Expands Leadership: Ex-Viatris CEO and Bristol Myers Legal Chief Join Board in Strategic Move - Stock Titan

Jul 24, 2025
pulisher
Jul 24, 2025

Novo Nordisk defeated in Wegovy patent dispute by Viatris - Yahoo Finance

Jul 24, 2025
pulisher
Jul 23, 2025

Is Viatris Inc. a good long term investmentOutperformance with explosive growth - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Novo Nordisk loses Wegovy patent fight against generics maker Viatris - Endpoints News

Jul 23, 2025
pulisher
Jul 23, 2025

Viatris’ Wegovy Copy Sheds One Novo Patent in Delaware Lawsuit - Bloomberg Law News

Jul 23, 2025
pulisher
Jul 23, 2025

Covering The Flaws In The Viatris Undervaluation Argument (NASDAQ:VTRS) - Seeking Alpha

Jul 23, 2025
pulisher
Jul 23, 2025

What to Expect From Viatris' Next Quarterly Earnings Report - MSN

Jul 23, 2025
pulisher
Jul 22, 2025

What To Expect From Viatris' Next Quarterly Earnings Report - Barchart.com

Jul 22, 2025
pulisher
Jul 22, 2025

VTRS Down on Late-Stage Study Failure of Eye Disease Drug - MSN

Jul 22, 2025
pulisher
Jul 21, 2025

Viatris down on late-stage trial setback for eye disorder therapy - MSN

Jul 21, 2025
pulisher
Jul 21, 2025

Agree To Buy Viatris At $5, Earn 3% Using Options - Nasdaq

Jul 21, 2025
pulisher
Jul 21, 2025

Viatris’ blepharitis ointment fails Phase III trial - Yahoo Finance

Jul 21, 2025
pulisher
Jul 21, 2025

Viatris Phase III MR-139 trial in blepharitis misses goal - The Pharma Letter

Jul 21, 2025
pulisher
Jul 21, 2025

Viatris Inc. (VTRS) Stock Analysis: A Deep Dive Into Its 28% Potential Upside For Investors - DirectorsTalk Interviews

Jul 21, 2025
pulisher
Jul 20, 2025

Viatris Inc. Stock Analysis and ForecastHigh-profit stock alerts - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 19, 2025

Viatris Announces Disappointing Phase 3 Study Results for MR-139 in Blepharitis, But Continues to Focus on Delivering Novel Therapies. - AInvest

Jul 19, 2025
pulisher
Jul 19, 2025

Viatris' Setback in Blepharitis Trial: A Harbinger or a Hurdle for Ophthalmic Innovation? - AInvest

Jul 19, 2025
pulisher
Jul 19, 2025

Trend Tracker for (VTRS) - news.stocktradersdaily.com

Jul 19, 2025
pulisher
Jul 19, 2025

Viatris Inc. Stock Forecasts: Trial Miss Pressures Recovery of Core Business - AInvest

Jul 19, 2025
pulisher
Jul 18, 2025

Viatris stock unchanged as Goldman maintains Neutral rating on trial miss By Investing.com - Investing.com South Africa

Jul 18, 2025

Viatris Inc Stock (VTRS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_specialty_generic RDY
$14.76
price up icon 0.41%
$134.19
price up icon 0.36%
$297.56
price down icon 0.19%
$14.39
price down icon 1.30%
$72.20
price down icon 0.29%
Cap:     |  Volume (24h):